Genovate Biotechnology Co Ltd (4130) - Total Liabilities

Latest as of December 2025: NT$126.05 Million TWD ≈ $3.97 Million USD

Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has total liabilities worth NT$126.05 Million TWD (≈ $3.97 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 4130 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Genovate Biotechnology Co Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Genovate Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Genovate Biotechnology Co Ltd (4130) total assets.

Genovate Biotechnology Co Ltd Competitors by Total Liabilities

The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Topower Co Ltd TWO:3226	Taiwan	NT$624.18 Million
Equillium Inc NASDAQ:EQ	USA	$3.57 Million
MFS High Income Municipal Closed Fund NYSE:CXE	USA	$83.53 Million
OBI Pharma TWO:4174	Taiwan	NT$495.56 Million
Hansae Yes24 KO:016450	Korea	₩2.11 Trillion
Hwaseung Enterprise Co Ltd KO:241590	Korea	₩882.77 Billion
Jw Life Science Corp KO:234080	Korea	₩94.80 Billion
Cheil Electric Wiring Devices Co. Ltd. KQ:199820	Korea	₩77.55 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Genovate Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Genovate Biotechnology Co Ltd (4130) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.74	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.09	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.08	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genovate Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genovate Biotechnology Co Ltd (2015–2025)

The table below shows the annual total liabilities of Genovate Biotechnology Co Ltd from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$126.05 Million ≈ $3.97 Million	-10.65%
2024-12-31	NT$141.08 Million ≈ $4.44 Million	+7.13%
2023-12-31	NT$131.69 Million ≈ $4.15 Million	-14.27%
2022-12-31	NT$153.60 Million ≈ $4.84 Million	+12.41%
2021-12-31	NT$136.65 Million ≈ $4.31 Million	-5.67%
2020-12-31	NT$144.87 Million ≈ $4.56 Million	-12.03%
2019-12-31	NT$164.68 Million ≈ $5.19 Million	-4.43%
2018-12-31	NT$172.32 Million ≈ $5.43 Million	-61.02%
2017-12-31	NT$442.06 Million ≈ $13.93 Million	+11.34%
2016-12-31	NT$397.04 Million ≈ $12.51 Million	+1.04%
2015-12-31	NT$392.95 Million ≈ $12.38 Million	--

About Genovate Biotechnology Co Ltd

TWO:4130 Taiwan Biotechnology

Market Cap

$115.03 Million

NT$3.65 Billion TWD

Market Cap Rank

#18750 Global

#1016 in Taiwan

Share Price

NT$26.70

Change (1 day)

-0.37%

52-Week Range

NT$18.75 - NT$36.80

All Time High

NT$56.99